Understand the disease, the care pathways and the evidence gaps.
Systemix helps rare-disease medical and biotech teams build a structured understanding of the evidence, care pathways and stakeholder perspectives that inform their next decision.
What do you need to understand about this disease?
You may know the published evidence well and still have questions about clinical practice. We help you investigate those questions across the specialists, centres and care pathways relevant to your programme.
Discuss your research needs- Where are patients diagnosed and treated?
- Which experts bring the experience we need?
- Where does clinical practice differ between countries?
- Which evidence gaps need closer investigation?
Our rare disease intelligence services
Rare disease landscaping
A structured read of the disease biology and evidence base, the diagnosis, referral and treatment pathways, and the specialists, centres and patient organisations around them.
TPP validation
Test the assumptions behind your target product profile with the clinicians, payers and patients closest to the disease.
Barrier and driver analysis
Research into the country-specific pathways, stakeholder views and conditions affecting adoption of your product.
How we work
Rare disease fields move quickly. We follow the published record closely and test what we find with the people close to the pathway.
Broad, structured tracking
We use AI-assisted search to gather what is published about a disease: research, congress activity, publications, specialists and centres, trials, and access signals.
Checked with people close to the pathway
What we find is tested in interviews with treating clinicians, researchers and others close to the patient journey, and their views are attributed as views.
Kept current where you need it
Where you want the picture kept current, we agree updates as part of scope, typically twice per year, or sooner when important developments affect your programme. Every figure resolves to its source, and uncertainty is stated rather than smoothed.
Rare diseaseexperts
Ground your European launch plans in local evidence
Which markets warrant closer investigation, what local intelligence is missing, and which launch assumptions need testing with stakeholders.
Read moreUnderstand the local barriers shaping rare-disease adoption
How referral pathways, stakeholder perspectives and evidence needs differ by market, and which questions your teams need to address.
Read moreDiscuss your research needs
Tell us the disease area, the priority markets and the decision in front of you, and we will come back with what a scoped engagement would cover.